Breaking News, Collaborations & Alliances

Monrol and FutureChem Sign Clinical Supply Contract

Will assess the efficacy and safety of repeated administration of Ludotadipep in patients with metastatic castration resistant prostate cancer (mCRPC).

Author Image

By: Charlie Sternberg

Associate Editor

Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) has reached an agreement in principal with FutureChem based in Seoul, South Korea, a radiopharmaceutical company, for the clinical supply of radioisotope, Lu-177 n.c.a. (Lutetium-177 non-carrier-added), to support FutureChem’s Investigational New Drug IND-enabling Phase 2 clinical trial with Ludotadipep, 177Lu-FC705 to assess the efficacy and safety for repeated administration of the recommended Ludotadipep dose in patients with metastatic castrati...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters